University of Washington School of Medicine, Seattle, WA, USA.
Department of Medicine, University of Washington, Seattle, WA, USA; Harborview Medical Center, Seattle, WA, USA.
Drug Alcohol Depend. 2019 Jul 1;200:71-77. doi: 10.1016/j.drugalcdep.2019.03.009. Epub 2019 May 1.
Office-based buprenorphine treatment is effective for opioid use disorder. Scant research has examined programmatic factors impacting successful initiation of treatment. To increase initiation of eligible patients, our buprenorphine program implemented changes to lower treatment thresholds. Most notable among these was elimination of a requirement that patients demonstrate abstinence from stimulants prior to initiating buprenorphine.
This observational, retrospective study included patients screened for primary care-based buprenorphine treatment under high- and low-threshold conditions from 2015 to 2017. Background characteristics and treatment data were extracted from the electronic medical record and clinical registry. Chi-squared tests were used to compare proportions of patients initiated within 90 days of screening and retained to 60 days after initiation, under both conditions. Multivariate logistic regression was employed to compare relative odds of buprenorphine initiation after adjustment for several covariates. All analyses were stratified by recent stimulant use.
The sample of 168 patients included 96 in the high-threshold group and 72 in the low-threshold group. Among patients with recent stimulant use, low-threshold conditions were associated with a higher proportion of patients initiated (69% versus 35%, p = 0.002) and higher relative odds of initiation (aOR = 7.01, 95% CI = 2.26-21.80) but also with a lower proportion of patients retained (63% versus 100%, p = 0.004). Among patients without recent stimulant use, low-threshold conditions did not change these measures by a statistically significant margin.
Lower-threshold policies may increase buprenorphine treatment initiation for patients with co-occurring stimulant use. However, patients using stimulants may require additional supports to remain engaged.
门诊美沙酮治疗对阿片类药物使用障碍有效。很少有研究探讨影响治疗成功启动的项目因素。为了增加符合条件的患者的治疗启动率,我们的美沙酮项目实施了降低治疗门槛的改变。其中最值得注意的是取消了患者在开始美沙酮治疗前必须证明戒除兴奋剂的要求。
本观察性、回顾性研究纳入了 2015 年至 2017 年在高、低门槛条件下接受初级保健美沙酮治疗筛查的患者。背景特征和治疗数据从电子病历和临床登记处提取。采用卡方检验比较在筛查后 90 天内启动治疗的患者比例和在启动后 60 天内保留治疗的患者比例,在两种条件下均进行比较。采用多变量逻辑回归比较调整了几个协变量后美沙酮启动的相对优势比。所有分析均按近期兴奋剂使用情况分层。
168 例患者的样本包括高门槛组 96 例和低门槛组 72 例。在近期使用兴奋剂的患者中,低门槛条件与更高比例的患者开始治疗(69%比 35%,p=0.002)和更高的相对启动优势比(aOR=7.01,95%CI=2.26-21.80)相关,但保留治疗的患者比例也较低(63%比 100%,p=0.004)。在没有近期使用兴奋剂的患者中,低门槛条件没有显著改变这些措施。
降低门槛政策可能会增加同时使用兴奋剂的患者接受美沙酮治疗的启动率。然而,使用兴奋剂的患者可能需要额外的支持来保持参与。